Home / Inspections / 1316082

FDA Inspection 1316082 — Aurobindo Pharma USA Inc

Aurobindo Pharma USA Inc — FEI 3008460374

The FDA completed an inspection of Aurobindo Pharma USA Inc on June 4, 2026 in East Windsor, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
June 4, 2026
Fiscal Year
2026
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
East Windsor, NJ (United States)

Facility

Other inspections at this facility

  • 1238442 (OAI Wed May 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 908515 (NAI Fri Dec 12 2014 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 783745 (NAI Wed May 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 736360 (VAI Fri Jul 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time))

FDA data resources